Fundraising FoxAtlas Venture — 2021 Investments
9 investments dated 2021 · listed companies and verified rows first · show all
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.
BiotechCambridge, US
Ankit Mahadevia(Executive Officer, Director)inStephen Garbacz(Executive Officer)inEsther Rajavelu(Director, President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer)in
BoardJean-Francois Formela(Director)inReza Halse(Director)Casper Breum(Director)
Board seatJean-François Formela· per SEC Form D
Co-investorsGV (Google Ventures)HEALTHCARE ROYALTY PARTNERSMRL Ventures FundOUP (Osage University Partners)RA CapitalAlphabet+1 more
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)
Board seatDavid Grayzel· per SEC Form D · $95M raise · filed Feb 2021
Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA Capital+9 more
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyBain Capital Life SciencesForesite CapitalFrazier Life SciencesOrbiMed5AM Ventures+7 more
Rectify Pharma is a biotechnology company developing therapies, with a pipeline that has included work in liver and metabolic disease areas.
BiotechDeep Tech
Rajesh Devraj(President and Chief Executive Officer)inRobert Hughes(Chief Scientific Officer)inPol Boudes(Chief Medical Officer)
Co-investorsDC Investment PartnersLongwood FundForbion
Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.
BiotechHealthtechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)
BoardDerek DiRocco(Director)inJulie Papanek Grant(Director)inJohn Josey(Director)inDaniel Becker(Director)
Board seatMichael Gladstone· per SEC Form D
Co-investorsAccess BiotechnologyCanaan PartnersViking GlobalAccess IndustriesRA CapitalThe Column Group
Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
BiotechCambridge, US
Andre Turenne(Executive Officer, Director)in
BoardJason Hafler(Director)inBruce Booth(Director)Daniel Becker(Director)
Co-investorsAccess BiotechnologyDigitalis VenturesSanofi VenturesAccess IndustriesAlexandria
Nimbus Engineering is a hardware company and online retailer developing energy transfer technology, including its patented Power Relay, a portable power outlet for home, office, and outdoor use.
CleantechDeep TechEnergyHardwareSan Francisco, US
Michael Gorman(Founder)in
Co-investorsFoothill VenturesAccess BiotechnologyBain Capital Life SciencesBiotechnology Value FundCommodore CapitalGV (Google Ventures)+2 more
FuseBase is an enterprise platform for deploying and managing AI agents across teams with role-based access controls, audit trails, and integrations to CRM, Slack, Teams, and email systems.
AI & Machine LearningEnterprise SoftwareFuture of WorkSaaSCleveland, US
Pavel Sher(CEO)Aaron Adsit(CRO)Denis Kibalko(CTO)
Co-investorsPre-Seed to SucceedYellow Rocks!Access BiotechnologyBain Capital Life SciencesBiotechnology Value FundCommodore Capital+3 more
Co-investorsTCG CrossoverAditum Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.